CLINICAL_TRIALS
ClinicalTrials.gov record update
An Interventional, Double-Blinded, 2-Arm Study to Investigate the Efficacy of Orally Administered Nirmatrelvir/Ritonavir Compared with Placebo/Ritonavir in Non-hospitalized Adult Participants Suffering from Post-COVID
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT05823896
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-25T22:27:04.785183+00:00
- Published At
- 2024-12-04T00:00:00+00:00
- Record Updated At
- 2024-12-04
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Post-COVID-19 Syndrome", "Long COVID", "Long Covid19", "COVID-19", "POTS - Postural Orthostatic Tachycardia Syndrome", "Post COVID-19 Condition", "Post-COVID Syndrome", "Post COVID-19 Condition, Unspecified", "Postinfectious Inflammation", "Postinfectious Disorder"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2024-12-04"- protocolSection.identificationModule.nctId
"NCT05823896"- protocolSection.identificationModule.officialTitle
"An Interventional, Double-Blinded, 2-Arm Study to Investigate the Efficacy of Orally Administered Nirmatrelvir/Ritonavir Compared with Placebo/Ritonavir in Non-hospitalized Adult Participants Suffering from Post-COVID"- protocolSection.statusModule.overallStatus
"COMPLETED"- protocolSection.designModule.phases
["PHASE2"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.